Healthcare Resource Use, Healthcare Costs, and Unmet Needs Among Patients Treated for EGFR-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
Findings highlight the importance of using the most effective 1L treatments to delay disease progression and reduce HRU and costs.
Authors
- Annalise Hilts
- Marie‐Hélène Lafeuille
- Pratyusha Vadagam
- Bruno Émond (ORCID: https://orcid.org/0000-0002-0060-765X)
- Jill Korsiak (ORCID: https://orcid.org/0000-0002-7509-4553)
- Dexter Waters (ORCID: https://orcid.org/0000-0002-9217-976X)
- I. А. Li (ORCID: https://orcid.org/0000-0002-9508-7502)
- David Michael Waterhouse (ORCID: https://orcid.org/0000-0001-5589-9939)
- Laura Morrison (ORCID: https://orcid.org/0000-0001-5471-9932)
- Patrick Lefèbvre (ORCID: https://orcid.org/0000-0002-2216-5442)
Institutions
- Johnson & Johnson (United States) (US)
- Group for Research in Decision Analysis (CA)
- Oncology Hematology Care (US)
Publication Details
- Journal
- Journal of health economics and outcomes research
- Published
- 2025-08-29
- DOI
- https://doi.org/10.36469/001c.142771
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52